ClinicalTrials.gg
CompletedNCT00185107Updated Sep 11, 2007

Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol

A Phase 4 interventional study of Colesevelam Hydrochloride and Ezetimibe in Hypercholesterolemia, sponsored by Daiichi Sankyo. Completed at 7 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2007-09-11.

Sponsored by Daiichi Sankyo · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
78th of 97
45 · median 148
Started
2005
with 13 others
Phase 4
31 of 98
1 open now
Registered
9th of 98
by date
Lead sponsor
2 of 98
Daiichi Sankyo

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 78th largest by enrollment of the 97 interventional ones that give a count, is one of 14 that started in 2005, is one of 31 in phase 4, and was the 9th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

Assess the efficacy of WelChol® plus Zetia® in treating patients with high cholesterol

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Safety
  • Efficacy
  • WelChol®
  • Zocor®
  • Zetia®
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-80 years of age, inclusive;
  • A history of primary hypercholesterolemia

Exclusion criteria

Exclusion Criteria:

  • Any serious disorders including pulmonary, hepatic, renal, gastrointestinal (including malabsorption), uncontrolled endocrine/ metabolic, hematologic/oncologic (within the last 5 years), neurologic and psychiatric diseases that would interfere with the conduct of the study or interpretation of the data;
  • Hepatic dysfunction including biliary cirrhosis, unexplained persistent liver function abnormality, and pre-existing gallbladder disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
45 participants
06

What researchers measure

Primary outcomes

  1. The percent change in LDL-C from the start of the study

Secondary outcomes

  1. - The absolute change in LDL-C from baseline

  2. - The percent change in LDL-C from baseline

  3. - The absolute changes and percent changes in TG, non-HDL-

  4. C, HDL-C, total cholesterol and other lipid measures

  5. - The percentages of patients who achieve target levels of LDL-C at the end of the study

07

Study locations

7 sites
  • Scripps Clinic
    San Diego, California 92128, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Radiant Research
    Overland Park, Kansas 66215, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Radiant Research
    Edina, Minnesota 55435, United States
  • Medical Office
    Statesville, North Carolina 28677, United States
  • Linder Clinical Trial Center
    Cincinnati, Ohio 45219, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 16, 2005
Start
Mar 2005
Completion
Oct 2005
Last update
Sep 11, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Sep 11, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00185107
Lead sponsor
Daiichi Sankyo
First posted
Sep 16, 2005
Start date
Mar 2005
Completion
Oct 2005
Last update
Sep 11, 2007

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Colesevelam · Ezetimibe

Start the discussion